Protalix BioTherapeutics, Inc. Balance Sheet
PLX|14 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
Protalix BioTherapeutics, Inc. had $82M in total assets and $43M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M | $17.8M | $51.2M | $76.4M | $54.8M | $86.4M | $52.0M | $27.0M | $35.9M | $81.3M |
| Accounts Receivable | $8.8M | $2.9M | $5.3M | $4.6M | $3.4M | $2.0M | $4.7M | $1.7M | $693.0K | - | $1.9M | $2.1M | $1.4M | $1.4M |
| Inventory | $25.7M | $21.2M | $19.0M | $16.8M | $18.0M | $13.1M | $8.2M | $7.8M | $5.2M | $5.8M | $6.7M | $8.0M | $4.0M | $279.0K |
| Current Assets | $66.7M | $60.1M | $69.9M | $44.9M | $61.7M | $55.7M | $32.5M | $62.7M | $71.9M | $85.9M | $65.5M | $97.9M | $61.2M | $32.5M |
| PP&E (Net) | $4.9M | $4.6M | $5.0M | $4.6M | $5.0M | $4.8M | $5.3M | $7.7M | $8.7M | $9.7M | $11.3M | $13.7M | $16.3M | $18.3M |
| Total Assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M | $45.4M | $72.2M | $82.2M | $97.3M | $78.5M | $113.3M | $78.7M | $51.8M |
| Current Liabilities | $26.5M | $25.6M | $45.5M | $32.4M | $33.2M | $86.5M | $40.2M | $22.8M | $66.2M | $11.2M | $26.2M | $26.7M | $25.8M | $18.7M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | $912.0K | $2.4M | $5.4M | - |
| Shareholders' Equity | $43.2M | -$10.6M | -$6.0M | -$27.0M | -$70.3M | -$52.9M | -$29.5M | $10.9M | -$55.6M | -$26.9M | -$3.4M | -$26.1M | -$11.3M | $15.9M |